Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma

References

• A clinical evaluation of the International Lymphoma Study Group classification of Non-Hodgkin's Lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Buske C, Dreyling M, Current management of follicular lymphomas. Br J Haematol 2007;136:191–202.
   PubMed Web of Science ®Google Scholar
• Luminari S, Federico M. Prognosis of follicular lymphomas. Hematol Oncol 2006;24:64–72.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Cavalli F, Longo DL. Text atlas of lymphomas. London: Martin Dunitz1999.
   Google Scholar
• Montoto S, Davies AJ, Matthews J, Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25:2426–2433.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Gine E, Montoto S, Bosch F, The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006;17:1539–1545.
   PubMed Web of Science ®Google Scholar
• Cogliatti SB, Schmid U. Who is WHO and what was REAL? Swiss Med Wkly 2002;132:607–617.
   PubMedGoogle Scholar
• Koster A, Tromp HA, Raemaekers JM, The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica 2007;92:184–190.
   PubMed Web of Science ®Google Scholar
• Kuppers R. Prognosis in follicular lymphoma–it's in the microenvironment. N Engl J Med 2004;351:2152–2153.
   PubMed Web of Science ®Google Scholar
• De Jong D. Molecular pathogenesis of follicular lymphoma:a cross talk of genetic and immunologic factors. J Clin Oncol 2005;23:6358–6363.
   PubMed Web of Science ®Google Scholar
• Glas AM, Kersten MJ, Delahaye LJ, Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005;105:301–307.
   PubMed Web of Science ®Google Scholar
• Glas AM, Knoops L, Delahaye L, Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390–398.
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider BF, Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169–2174.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Camacho FI, The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 2006;91:1605–1612.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350–5357.
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Sander B, Christensson B, CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007;13:388–397.
   PubMed Web of Science ®Google Scholar
• Koster A, van Krieken JH, Mackenzie MA, Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 2005;11:154–161.
   PubMed Web of Science ®Google Scholar
• Farinha P, Kyle A, Minchinton A, Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 2010;95:2157–2160.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–545.
   PubMed Web of Science ®Google Scholar
• Kadowaki N. The divergence and interplay between pDC and mDC in humans. Front Biosci 2009;14:808–817.
   Google Scholar
• Gascoyne RD, Rosenwald A, Poppema S, Prognostic biomarkers in malignant lymphomas. Leuk Lymphoma 2010;51(Suppl. 1):11–19.
   PubMed Web of Science ®Google Scholar
• Siegal FP, Kadowaki N, Shodell M, The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835–1837.
   PubMed Web of Science ®Google Scholar
• Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275–306.
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Antonenko S, Lau JY, Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000;192:219–226.
   PubMed Web of Science ®Google Scholar
• Rohatiner AZ, Gregory WM, Peterson B, Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215–2223.
   PubMed Web of Science ®Google Scholar
• Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943–1949.
   PubMed Web of Science ®Google Scholar
• Hedvat CV, Hegde A, Chaganti RS, Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002;33:968–974.
   PubMed Web of Science ®Google Scholar
• Roche PC, Hsi ED. Immunohistochemistry – principles and advances. Manual of clinical laboratory immunology. In: Rose NR, Hamilton RG, Detrick B, editors. 6th edWashington, DC: American Society for Microbiology Press2002. pp. 380–386.
   Google Scholar
• Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577–580.
   PubMed Web of Science ®Google Scholar
• Olweus J, BitMansour A, Warnke R, Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA 1997;94:12551–12556.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J R Stat Assoc 1972;34:187–220.
   Web of Science ®Google Scholar
• Hartmann E, Wollenberg B, Rothenfusser S, Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003;63:6478–6487.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Burg G, Fah J, Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T-cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 1997; 150:641–651.
   PubMed Web of Science ®Google Scholar
• Enk AH, Jonuleit H, Saloga J, Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997;73:309–316.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996;170:101–110.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Corak J, Ciernik IF, Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483–490.
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Freedman AS. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma. Semin Hematol 2008;45:85–89.
   PubMed Web of Science ®Google Scholar
• Bekisz J, Baron S, Balinsky C, Antiproliferative properties of type I and type II interferon. Pharmaceuticals 2010;3:994–1015.
   Google Scholar
• Baldo P, Rupolo M, Compagnoni A, Interferon-alpha for maintenance of follicular lymphoma. Cochrane Database Syst Rev 2010;(1): CD004629.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Ganguly S, Patel V. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol 2009;2:14.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Kelly JL, Neuberg D, Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009;146:282–291.
   PubMed Web of Science ®Google Scholar
• Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008;27:161–167.
   PubMed Web of Science ®Google Scholar
• Rothenfusser S, Hornung V, Ayyoub M, CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood 2004;103:2162–2169.
   PubMed Web of Science ®Google Scholar
• Harjunpaa A, Taskinen M, Nykter M, Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol 2006;135:33–42.
   PubMed Web of Science ®Google Scholar
• Lee AM, Clear AJ, Calaminici M, Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052–5059.
   PubMed Web of Science ®Google Scholar